Acne in Patients with Skin of Color: Practical Management

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Acne vulgaris is a prevalent and non-discriminatory condition affecting individuals of all races and ethnicities. As people with skin of color make up a rapidly expanding segment of the US population, dermatologic care must evolve accordingly to address their distinct concerns. Patients with skin of color with acne can be particularly challenging, given their potential for cosmetically disturbing complications, including post-inflammatory hyperpigmentation and keloid development. A variety of treatments have been shown to be effective in preventing or treating these complications. Topical retinoids are considered first-line therapy for acne in patients of color; topical alternatives include azelaic acid, dapsone, and antimicrobials. Hydroquinone may be used in combating post-inflammatory hyperpigmentation, specifically. For more severe acne, oral agents, including oral antibiotics or isotretinoin, may be used. Most recently, various lasers and phototherapies have been suggested for their safety and efficacy in patients with skin of color with acne. Ultimately, recognizing the clinical and histologic differences, as well as the variations in treatment regimens for darker skin types will allow for better care and patient satisfaction.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361–72. doi:10.1016/S0140-6736(11)60321-8.

    PubMed  Article  Google Scholar 

  2. 2.

    White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol. 1998;39(2 Pt 3):S34–7.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Bureau UC. US Census Bureau news: more diversity, slower growth; 2004. http://www.census.gov/Press-Release/www/releases/archives/population/001720.html (Accessed 6 June 2013).

  4. 4.

    Shah SK, Alexis AF. Acne in skin of color: practical approaches to treatment. J Dermatol Treat. 2010;21(3):206–11. doi:10.3109/09546630903401496.

    Article  Google Scholar 

  5. 5.

    Halder RM, Brooks HL, Callender VD. Acne in ethnic skin. Dermatol Clin. 2003;21(4):609–15, vii.

    Google Scholar 

  6. 6.

    Schachner L, Ling NS, Press S. A statistical analysis of a pediatric dermatology clinic. Pediatr Dermatol. 1983;1(2):157–64.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Child FJ, Fuller LC, Higgins EM, Du Vivier AW. A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol. 1999;141(3):512–7.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80(5):387–94.

    PubMed  Google Scholar 

  9. 9.

    Halder RM, Grimes PE, McLaurin CI, et al.. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32(4):388–390.

    Google Scholar 

  10. 10.

    Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin. 2003;21(4):601–7.

    PubMed  Article  Google Scholar 

  11. 11.

    Arsouze A, Fitoussi C, Cabotin PP, Chaine B, Delebecque C, Raynaud E, et al. Presenting skin disorders in black Afro-Caribbean patients: a multicentre study conducted in the Paris region. Annales de dermatologie et de venereologie. 2008;135(3):177–82. doi:10.1016/j.annder.2007.11.008.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Dunwell P, Rose A. Study of the skin disease spectrum occurring in an Afro-Caribbean population. Int J Dermatol. 2003;42(4):287–9.

    PubMed  Article  Google Scholar 

  13. 13.

    Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012;11(4):466–73.

    PubMed  Google Scholar 

  14. 14.

    Perkins AC, Cheng CE, Hillebrand GG, Miyamoto K, Kimball AB. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venereol. 2011;25(9):1054–60. doi:10.1111/j.1468-3083.2010.03919.x.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010;3(4):24–38.

    PubMed Central  PubMed  Google Scholar 

  16. 16.

    Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20–31.

    PubMed Central  PubMed  Google Scholar 

  17. 17.

    Callender VD. Acne in ethnic skin: special considerations for therapy. Dermatol Ther. 2004;17(2):184–95. doi:10.1111/j.1396-0296.2004.04019.x.

    PubMed  Article  Google Scholar 

  18. 18.

    Grimes PE, Stockton T. Pigmentary disorders in blacks. Dermatol Clin. 1988;6(2):271–81.

    CAS  PubMed  Google Scholar 

  19. 19.

    Coley MK, Alexis AF. Managing common dermatoses in skin of color. Semin Cutan Med Surg. 2009;28(2):63–70. doi:10.1016/j.sder.2009.04.006.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Halder RM, Holmes YC, Bridgeman-Shah S, Klingman AM. A clinicohistopathological study of acne vulgaris in black females. J Invest Dermatol. 1996;106:888.

    Google Scholar 

  21. 21.

    Halder RM, Roberts CI, Nootheti PK. Cutaneous diseases in the black races. Dermatol Clin. 2003;21(4):679–87, ix.

    Google Scholar 

  22. 22.

    Taylor SC, Cook-Bolden F, Rahman Z, et al. Acne vulgaris in skin of color. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):S98–106.

    Google Scholar 

  23. 23.

    Lacz NL, Vafaie J, Kihiczak NI, Schwartz RA. Postinflammatory hyperpigmentation: a common but troubling condition. Int J Dermatol. 2004;43(5):362–5. doi:10.1111/j.1365-4632.2004.02267.x.

    PubMed  Article  Google Scholar 

  24. 24.

    Kelly AP. Update on the management of keloids. Semin Cutan Med Surg. 2009;28(2):71–6. doi:10.1016/j.sder.2009.04.002.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Kelly AP. Keloids: pathogenesis and treatment. Cosmetic Dermatol. 2003;16:29–32.

    Google Scholar 

  26. 26.

    Marneros AG, Norris JE, Olsen BR, Reichenberger E. Clinical genetics of familial keloids. Arch Dermatol. 2001;137(11):1429–34.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Cole PD, Hatef DA, Taylor S, Bullocks JM. Skin care in ethnic populations. Semin Plastic Surg. 2009;23(3):168–72. doi:10.1055/s-0029-1224795.

    Article  Google Scholar 

  28. 28.

    Wilkins JW Jr, Voorhees JJ. Prevalence of nodulocystic acne in white and Negro males. Arch Dermatol. 1970;102(6):631–4.

    PubMed  Article  Google Scholar 

  29. 29.

    Lee CS, Lim HW. Cutaneous diseases in Asians. Dermatol Clin. 2003;21(4):669–77.

    PubMed  Article  Google Scholar 

  30. 30.

    Luther N, Darvin ME, Sterry W, Lademann J, Patzelt A. Ethnic differences in skin physiology, hair follicle morphology and follicular penetration. Skin Pharmacol Physiol. 2012;25(4):182–91. doi:10.1159/000337933.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Nicolaides N, Rothman S. Studies on the chemical composition of human hair fat: II. The overall composition with regard to age, sex and race. J Invest Dermatol. 1953;21(1):9–14.

    CAS  PubMed  Google Scholar 

  32. 32.

    Kligman AM, Shelley WB. An investigation of the biology of the human sebaceous gland. J Invest Dermatol. 1958;30(3):99–125.

    CAS  PubMed  Google Scholar 

  33. 33.

    Pochi PE, Strauss JS. Sebaceous gland activity in black skin. Dermatol Clin. 1988;6(3):349–51.

    CAS  PubMed  Google Scholar 

  34. 34.

    Grimes P, Edison BL, Green BA, Wildnauer RH. Evaluation of inherent differences between African American and white skin surface properties using subjective and objective measures. Cutis. 2004;73(6):392–6.

    PubMed  Google Scholar 

  35. 35.

    Roh M, Han M, Kim D, Chung K. Sebum output as a factor contributing to the size of facial pores. Br J Dermatol. 2006;155(5):890–4. doi:10.1111/j.1365-2133.2006.07465.x.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Rawlings AV. Ethnic skin types: are there differences in skin structure and function? Int J Cosmet Sci. 2006;28(2):79–93. doi:10.1111/j.1467-2494.2006.00302.x.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Kuenali S. Retinoids. Dermatology. 2nd ed. Elsevier Mosby; 2009.

  38. 38.

    Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328(20):1438–43. doi:10.1056/NEJM199305203282002.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77(1):45–50.

    PubMed  Google Scholar 

  40. 40.

    Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55(6):1048–65. doi:10.1016/j.jaad.2006.02.009.

    PubMed  Article  Google Scholar 

  41. 41.

    Halder RM. The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol. 1998;39(2 Pt 3):S98–103.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Jacyk WK, Mpofu P. Adapalene gel 0.1 % for topical treatment of acne vulgaris in African patients. Cutis. 2001;68(4 Suppl):48–54.

    Google Scholar 

  43. 43.

    Czernielewski J, Poncet M, Mizzi F. Efficacy and cutaneous safety of adapalene in black patients versus white patients with acne vulgaris. Cutis. 2002;70(4):243–8.

    PubMed  Google Scholar 

  44. 44.

    Zhu XJ, Tu P, Zhen J, et al. Adapalene gel 0.1%: effective and well tolerated in the topical treatment of acne vulgaris in Chinese patients. Cutis. 2001;68(4 Suppl):55–9.

    Google Scholar 

  45. 45.

    Kawashima M, Harada S, Loesche C, Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study. J Dermatol Sci. 2008;49(3):241–8. doi:10.1016/j.jdermsci.2007.09.012.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Fernandez-Obregon A, Davis MW. The BEST study: evaluating efficacy by selected demographic subsets. Cutis. 2003;71(2 Suppl):18–26.

    PubMed  Google Scholar 

  47. 47.

    Shavin J, Weiss J. Implications of the BEST study. Cutis. 2003;71(2 Suppl):35–6.

    PubMed  Google Scholar 

  48. 48.

    Taylor SC. Utilizing combination therapy for ethnic skin. Cutis. 2007;80(1 Suppl):15–20.

    PubMed  Google Scholar 

  49. 49.

    Callender VD, Preston N, Osborn C, Johnson L, Gottschalk RW. A meta-analysis to investigate the relation between Fitzpatrick skin types and tolerability of adapalene-benzoyl peroxide topical gel in subjects with mild or moderate acne. J Clin Aesthet Dermatol. 2010;3(8):15–9.

    PubMed Central  PubMed  Google Scholar 

  50. 50.

    Eichenfield LF, Krakowski AC. Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. J Drugs Dermatol. 2012;11(7):818–24.

    CAS  PubMed  Google Scholar 

  51. 51.

    Cook-Bolden FE. Treatment of moderate to severe acne vulgaris in a Hispanic population: a post-hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. J Drugs Dermatol. 2012;11(4):455–9.

    CAS  PubMed  Google Scholar 

  52. 52.

    Callender VD. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy and tolerability of treatment in moderate to severe acne. J Drugs Dermatol. 2012;11(5):643–8.

    CAS  PubMed  Google Scholar 

  53. 53.

    Schlessinger J, Menter A, Gold M, Leonardi C, Eichenfield L, Plott RT, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(6):607–15.

    PubMed  Google Scholar 

  54. 54.

    Callender VD, Young CM, Kindred C, et al. Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced post-inflammatory hyperpigmentation in patients with skin of color. J Clin Aesthet Dermatol. 2012;5(7):25–32.

    Google Scholar 

  55. 55.

    Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439 e1–10. doi:10.1016/j.jaad.2006.10.005.

    Google Scholar 

  56. 56.

    Fleischer AB Jr, Shalita A, Eichenfield LF, Abramovits W, Lucky A, Garrett S, et al. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. J Drugs Dermatol. 2010;9(1):33–40.

    PubMed  Google Scholar 

  57. 57.

    Research CfDEa. Application number 21-794, Aczone (dapsone) gel 5%. Microbiology Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021794s000_MicroR (Accessed 8 June 2013).

  58. 58.

    Piette WW, Taylor S, Pariser D, Jarratt M, Sheth P, Wilson D. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Arch Dermatol. 2008;144(12):1564–70. doi:10.1001/archdermatol.2008.518.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Webster GF. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? J Drugs Dermatol. 2010;9(5):532–6.

    PubMed  Google Scholar 

  60. 60.

    Lucky AW, Maloney JM, Roberts J, Taylor S, Jones T, Ling M, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol. 2007;6(10):981–7.

    PubMed  Google Scholar 

  61. 61.

    Aczone (dapsone) gel 5 % [package insert]. Irvine: Allergan Inc.; 2009.

  62. 62.

    Webster G. Combination azelaic acid therapy for acne vulgaris. J Am Acad Dermatol. 2000;43(2 Pt 3):S47–50.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Gollnick HP, Graupe K, Zaumseil RP. Azelaic acid 15% gel in the treatment of acne vulgaris: combined results of two double-blind clinical comparative studies. J German Soc Dermatol. 2004;2(10):841–7.

    Google Scholar 

  64. 64.

    Fitton A, Goa KL. Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs. 1991;41(5):780–98.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Hsu S, Quan LT. Topical antibacterial agents. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy; 2001. p. 473–496.

  66. 66.

    Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol. 2011;10(6):586–90.

    CAS  PubMed  Google Scholar 

  67. 67.

    Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20(5):945–59.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Bolognia J, Jorizzo JL, Rapini RP. Dermatology. New York: Mosby; 2003.

    Google Scholar 

  69. 69.

    Chandra M, Levitt J, Pensabene CA. Hydroquinone therapy for post-inflammatory hyperpigmentation secondary to acne: not just prescribable by dermatologists. Acta Derm Venereol. 2012;92(3):232–5. doi:10.2340/00015555-1225.

    CAS  PubMed  Article  Google Scholar 

  70. 70.

    Glenn M, Grimes PE, Pitt E, Chalet M, Kelly AP. Evaluation of clinical and light microscopic effects of various concentrations of hydroquinone [abstract]. Clin Res. 1991;39:83A.

    Google Scholar 

  71. 71.

    Costa A, Moises TA, Cordero T, Alves CR, Marmirori J. Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma. Anais brasileiros de dermatologia. 2010;85(5):613–20.

    PubMed  Article  Google Scholar 

  72. 72.

    Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20(5):308–13. doi:10.1111/j.1529-8019.2007.00144.x.

    PubMed  Article  Google Scholar 

  73. 73.

    Kelly AP, Sampson DD. Recalcitrant nodulocystic acne in black Americans: treatment with isotretinoin. J Natl Med Assoc. 1987;79(12):1266–70.

    CAS  PubMed  Google Scholar 

  74. 74.

    Ho SG, Chan HH. The Asian dermatologic patient: review of common pigmentary disorders and cutaneous diseases. Am J Clin Dermatol. 2009;10(3):153–68. doi:10.2165/00128071-200910030-00002.

    PubMed  Article  Google Scholar 

  75. 75.

    Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18(10):821–32. doi:10.1111/j.1600-0625.2009.00890.x.

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    Goulden V. Guidelines for the management of acne vulgaris in adolescents. Pediatr Drugs. 2003;5(5):301–13.

    Google Scholar 

  77. 77.

    Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1–37. doi:10.1067/mjd.2003.618.

    PubMed  Article  Google Scholar 

  78. 78.

    Tanghetti E. The impact and importance of resistance. Cutis. 2007;80(1 Suppl):5–9.

    PubMed  Google Scholar 

  79. 79.

    Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology. 2003;206(1):54–6. doi:67822.

    CAS  PubMed  Article  Google Scholar 

  80. 80.

    Ebede TL, Arch EL, Berson D. Hormonal treatment of acne in women. J Clin Aesthet Dermatol. 2009;2(12):16–22.

    PubMed Central  PubMed  Google Scholar 

  81. 81.

    Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2009(2):CD000194. doi:10.1002/14651858.CD000194.pub2.

  82. 82.

    Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43(3):498–502. doi:10.1067/mjd.2000.105557.

    CAS  PubMed  Article  Google Scholar 

  83. 83.

    Kamangar F, Shinkai K. Acne in the adult female patient: a practical approach. Int J Dermatol. 2012;51(10):1162–74. doi:10.1111/j.1365-4632.2012.05519.x.

    PubMed  Article  Google Scholar 

  84. 84.

    Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol. 2008;58(1):60–2. doi:10.1016/j.jaad.2007.09.024.

    PubMed  Article  Google Scholar 

  85. 85.

    Roberts WE. Chemical peeling in ethnic/dark skin. Dermatol Ther. 2004;17(2):196–205. doi:10.1111/j.1396-0296.2004.04020.x.

    PubMed  Article  Google Scholar 

  86. 86.

    Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in black patients: a comparative study. Dermatol Surg. 1997;23(3):171–4 (discussion 5).

    Google Scholar 

  87. 87.

    Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999;25(1):18–22.

    CAS  PubMed  Article  Google Scholar 

  88. 88.

    Godse K, Sakhia J. Triple combination and glycolic peels in post-acne hyperpigmentation. J Cutan Aesthet Surg. 2012;5(1):60–1. doi:10.4103/0974-2077.94335.

    PubMed Central  PubMed  Article  Google Scholar 

  89. 89.

    Yeung CK, Shek SY, Yu CS, Kono T, Chan HH. Treatment of inflammatory facial acne with 1,450-nm diode laser in type IV to V Asian skin using an optimal combination of laser parameters. Dermatol Surg. 2009;35(4):593–600. doi:10.1111/j.1524-4725.2009.01097.x.

    CAS  PubMed  Article  Google Scholar 

  90. 90.

    Rojanamatin J, Choawawanich P. Treatment of inflammatory facial acne vulgaris with intense pulsed light and short contact of topical 5-aminolevulinic acid: a pilot study. Dermatol Surg. 2006;32(8):991–6 (discussion 6–7). doi:10.1111/j.1524-4725.2006.32221.x.

  91. 91.

    Kim S, Cho KH. Treatment of facial postinflammatory hyperpigmentation with facial acne in Asian patients using a Q-switched neodymium-doped yttrium aluminum garnet laser. Dermatol Surg. 2010;36(9):1374–80. doi:10.1111/j.1524-4725.2010.01643.x.

    CAS  PubMed  Article  Google Scholar 

  92. 92.

    Chua SH, Ang P, Khoo LS, Goh CL. Nonablative 1450-nm diode laser in the treatment of facial atrophic acne scars in type IV to V Asian skin: a prospective clinical study. Dermatol Surg. 2004;30(10):1287–91. doi:10.1111/j.1524-4725.2004.30402.x.

    PubMed  Article  Google Scholar 

  93. 93.

    Alexis AF. Fractional laser resurfacing of acne scarring in patients with Fitzpatrick skin types IV–VI. J Drugs Dermatol. 2011;10(12 Suppl):s6–7.

    PubMed  Google Scholar 

  94. 94.

    Clark CM, Silverberg JI, Alexis AF. A retrospective chart review to assess the safety of nonablative fractional laser resurfacing in Fitzpatrick skin types IV to VI. J Drugs Dermatol. 2013;12(4):428–31.

    PubMed  Google Scholar 

  95. 95.

    Griffin AC. Laser resurfacing procedures in dark-skinned patients. Aesthet Surg J. 2005;25(6):625–7. doi:10.1016/j.asj.2005.09.019.

    CAS  PubMed  Article  Google Scholar 

  96. 96.

    Badawi A, Tome MA, Atteya A, Sami N, Morsy IA. Retrospective analysis of non-ablative scar treatment in dark skin types using the sub-millisecond Nd:YAG 1,064 nm laser. Lasers Surg Med. 2011;43(2):130–6. doi:10.1002/lsm.21031.

    PubMed  Article  Google Scholar 

  97. 97.

    Ruiz-Esparza J, Gomez JB. Nonablative radiofrequency for active acne vulgaris: the use of deep dermal heat in the treatment of moderate to severe active acne vulgaris (thermotherapy): a report of 22 patients. Dermatol Surg. 2003;29(4):333–9 (discussion 9).

    Google Scholar 

  98. 98.

    Elsaie ML, Choudhary S, Leiva A, Nouri K. Nonablative radiofrequency for skin rejuvenation. Dermatol Surg. 2010;36(5):577–89. doi:10.1111/j.1524-4725.2010.01510.x.

    CAS  PubMed  Article  Google Scholar 

  99. 99.

    Lee SJ, Goo JW, Shin J, Chung WS, Kang JM, Kim YK, et al. Use of fractionated microneedle radiofrequency for the treatment of inflammatory acne vulgaris in 18 Korean patients. Dermatol Surg. 2012;38(3):400–5. doi:10.1111/j.1524-4725.2011.02267.x.

    CAS  PubMed  Article  Google Scholar 

  100. 100.

    Terrell S, Aires D, Schweiger ES. Treatment of acne vulgaris using blue light photodynamic therapy in an African-American patient. J Drugs Dermatol. 2009;8(7):669–71.

    PubMed  Google Scholar 

  101. 101.

    Cayce KA, McMichael AJ, Feldman SR. Hyperpigmentation: an overview of the common afflictions. Dermatol Nursing. 2004;16(5):401–6, 13–16 (quiz 17).

    Google Scholar 

Download references

Conflict of interest

There are no conflicts of interest or sources of funding for any authors involved in the writing of this manuscript.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Natalie C. Yin.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yin, N.C., McMichael, A.J. Acne in Patients with Skin of Color: Practical Management. Am J Clin Dermatol 15, 7–16 (2014). https://doi.org/10.1007/s40257-013-0049-1

Download citation

Keywords

  • Acne
  • Isotretinoin
  • Tretinoin
  • Azelaic Acid
  • Tazarotene